@article{111171,
  keywords = {Animals, Humans, Mice, Mice, Transgenic, Antibodies, Monoclonal, Antineoplastic Agents, Osteoblasts, Bone Neoplasms, Jagged-1 Protein, Xenograft Model Antitumor Assays},
  author = {Hanqiu Zheng and Yangjin Bae and Sabine Kasimir-Bauer and Rebecca Tang and Jin Chen and Guangwen Ren and Min Yuan and Mark Esposito and Wenyang Li and Yong Wei and Minhong Shen and Lanjing Zhang and Nikolai Tupitsyn and Klaus Pantel and Chadwick King and Jan Sun and Jodi Moriguchi and Helen Toni Jun and Angela Coxon and Brendan Lee and Yibin Kang},
  title = {Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy},
  abstract = {<p>Bone metastasis is a major health threat to breast cancer patients. Tumor-derived Jagged1 represents a central node in mediating tumor-stromal interactions that promote osteolytic bone metastasis. Here, we report the development of a highly effective fully human monoclonal antibody against Jagged1 (clone 15D11). In addition to its inhibitory effect on bone metastasis of Jagged1-expressing tumor cells, 15D11 dramatically sensitizes bone metastasis to chemotherapy, which induces Jagged1 expression in osteoblasts to provide a survival niche for cancer cells. We further confirm the bone metastasis-promoting function of osteoblast-derived Jagged1 using osteoblast-specific Jagged1 transgenic mouse model. These findings establish 15D11 as a potential therapeutic agent for the prevention or treatment of bone metastasis.</p>
},
  year = {2017},
  journal = {Cancer Cell},
  volume = {32},
  pages = {731-747.e6},
  month = {12/2017},
  issn = {1878-3686},
  doi = {10.1016/j.ccell.2017.11.002},
  language = {eng},
}